Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

E! 113377 NPS-REFORM_Development of the scale-up and proactive platform for forensic..._Linköpings universitet

Reference number
Coordinator Linköpings universitet - IFM, Linköping University
Funding from Vinnova SEK 2 000 000
Project duration October 2019 - October 2022
Status Ongoing
Venture Eurostars

Purpose and goal

The main project goal is to develop and apply a platform for production of certified reference material (CRM) through upscaled synthesis of key intermediates, which subsequently can be transformed into CRMs of desired NPS and NPS metabolites (including 13C labelling). A proactive approach, rather than a reactive, will be applied aiming at producing CRMs faster than what is the case today. A second project goal is to improve the understanding of NPS metabolism and receptor activation. The project will mainly target potent NPS like synthetic opioids and cannabinoids.

Expected results and effects

Fast access to certified reference material (CRM) is necessary for forensic and toxicological laboratories to develop and implement analytical methods for detection of NPS. Hence, the substances to be produced in the current project are important in the fight against narcotic substances. The knowledge about NPS metabolism is valuable as native NPS often cannot be detected in urine, why intake must be proven based on metabolites that provide longer detection windows. Moreover, the receptor activation studies will give guidance on the potency of emerging NPS and NPS metabolites.

Planned approach and implementation

Linköping university will focus on metabolites of NPS. Incubation of selected NPS together with human hepatocytes will be made to identify metabolic pathways and key metabolites, which will subsequently be synthesized in larger scale using the developed production platform to produce CRMs. The certification is made by Chiron Pharmasynth AS. Moreover, the potency of the synthesized emerging NPS and their metabolites will be targeted in receptor activation studies.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 6 September 2019

Reference number 2019-03566

Page statistics